seqWell
seqWell is a genomics reagents company that develops and manufactures next-generation sequencing (NGS) library preparation kits and transposase-based technologies for life sciences research, enabling simple, scalable, and high-throughput sequencing workflows. The company's core technology is its proprietary TnX transposase, which provides improved uniformity of coverage with increased library yield and complexity…
Funding snapshot
About
seqWell is a genomics reagents company that develops and manufactures next-generation sequencing (NGS) library preparation kits and transposase-based technologies for life sciences research, enabling simple, scalable, and high-throughput sequencing workflows. The company's core technology is its proprietary TnX transposase, which provides improved uniformity of coverage with increased library yield and complexity compared to conventional transposases. seqWell's product portfolio includes ExpressPlex 2.0 Library Prep Kit for high-throughput tagmentation-based library preparation that combines multiple steps into one, reducing time to data and improving quality control; LongPlex Multiplexing Kit for long-read sequencing library preparation; MosaiX Library Prep Kit; AgriPrep Library Prep Kit for agrigenomics applications; purePlex auto-normalization technology that eliminates individual sample quantification and normalization; and the Tagify platform of custom-loaded transposases including Tagify Custom-loaded Transposase, Tagify i5 UMI Adapter-loaded Transposase, and Tagify TnX Universal Adapters. The company's plexWell platform enables parallelized library prep allowing multiplexing of hundreds to thousands of distinct samples with an order-of-magnitude improvement in sample throughput for benchtop NGS instruments. seqWell serves applications including agrigenomics, antibody development, gene editing quality control, low-pass whole genome sequencing, microbial sequencing, plasmid and amplicon sequencing, and single-cell library preparation. The company's customers include leading research institutions and biotech companies such as Editas Medicine, Northwestern University, Galatea Bio, Octant Bio, SUNY Upstate Medical University, NIH, and the University of Minnesota Genomics Center, with reported improvements from 75% to 95-99% success rates. Founded in 2014 and headquartered in Beverly, Massachusetts, seqWell has raised $24.5M in Series C funding from investors including RCT, Broadoak Capital Partners, Current Investors, Codexis, and CYwP Funds.
Business model
Genomics > Enabling Technologies > Kits and Reagents > NGS Reagents,
Life Sciences Platforms and Tools > Research Reagents and Kits > Genomics > NGS Reagents
Team background
College Wise > University of Chicago
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.